An open, phase I study of cediranib in patients with acute myeloid leukemia (AML)

被引：0

作者：

Fiedler, Walter ^{[1
]}

Mesters, Rolf ^{[2
]}

Heuser, Michael ^{[3
]}

Ehninger, Gerhard ^{[4
]}

Ottman, Oliver G. ^{[5
]}

Berdel, Wolfgang E. ^{[2
]}

Zirrgiebel, Ute ^{[6
]}

Robertson, Jane ^{[7
]}

Puchalski, Thomas A. ^{[8
]}

Brave, Sandra R. ^{[7
]}

Juergensmeier, Juliane M. ^{[7
]}

Serve, Hubert ^{[2
,5
]}

机构：

[1] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[2] Univ Hosp, Munster, Germany

[3] Hannover Med Sch, D-3000 Hannover, Germany

[4] Univ Hosp Carl Gustav Carus, Dresden, Germany

[5] Univ Hosp, Frankfurt, Germany

[6] ProQinase GmbH, Freiburg, Germany

[7] AstraZeneca, Macclesfield, Cheshire, England

[8] AstraZeneca, Wilmington, DE USA

来源：

BLOOD | 2007年 / 110卷 / 11期

关键词：

D O I：

10.1182/blood.V110.11.895.895

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

895

引用

页码：273A / 273A

页数：1

共 50 条

[21] Management of Acute Myeloid Leukemia (AML) in Older Patients
Abdallah, Maya
Xie, Zhuoer
Ready, Audrey
Manogna, Dharmini
Mendler, Jason H.
Loh, Kah Poh
CURRENT ONCOLOGY REPORTS, 2020, 22 (10)
[22] Prognosis factor study in acute myeloid leukemia (AML).
Lacombe, F
Marit, G
Dumain, P
Faberes, C
Boiron, JM
Belloc, F
ConyMakhoul, P
BilhouNabera, C
Bernard, P
Reiffers, J
BLOOD, 1997, 90 (10) : 284 - 284
[23] A Conventional Cytogenetic Study of Acute Myeloid Leukemia (AML) in 340 Brazilian patients
Schmid-Braz, Ana Teresa
Wuicik-Merfort, Lismeri
Borgonovo, Tamara
Jamur, Valderez R.
Caporal, Fernando Augusto
Cavalli, Iglenir Joao
Beltrame, Miriam
Malvezzi, Marister
CHROMOSOME RESEARCH, 2013, 21 : S77 - S77
[24] A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia (AML).
Yee, Karen W. L.
Minden, Mark D.
Brandwein, Joseph
Schimmer, Aaron
Schuh, Andre
Gupta, Vikas
Messner, Hans A.
Foley, Ronan
Wasi, Parven
Zwiebel, James A.
Leber, Brian
BLOOD, 2007, 110 (11) : 277A - 277A
[25] Phase I/IIa trial of volasertib combined with decitabine in patients with acute myeloid leukemia (AML) ineligible for intensive therapy
Cortes, Jorge E.
Podoltsev, Nikolai
Rajeswari, Sushmita
Guo, Zhenchao
Taube, Tillmann
Uy, Geoffrey L.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S193 - S193
[26] Open-Label, Multi-Center Phase I Dose Escalation Study with Lenalidomide In Patients with Acute Myeloid Leukemia
Huetter, Marie-Luise
Fiedler, Walter
Kuendgen, Andrea
Krauter, Juergen
von Lilienfeld-Toal, Marie
Kayser, Sabine
Rafler, Heidi
Doehner, Hartmut
Schlenk, Richard F.
BLOOD, 2010, 116 (21) : 1350 - 1351
[27] Phase II study of the histone deacetylase inhibitor depsipeptide in patients with relapsed or refractory acute myeloid leukemia (AML).
Odenike, OM
Alkan, S
Godwin, JE
Brandt, SJ
Sher, D
Stiff, PJ
Corum, L
Vokes, EE
Larson, R
Stock, W
BLOOD, 2003, 102 (11) : 241B - 242B
[28] A phase I dose escalating study of infusion of a bispecific antibody (BsAb) for relapsed/refractory acute myeloid leukemia (AML).
Chen, J
Bashey, A
Holman, P
Carrier, E
Law, P
Ball, ED
BLOOD, 1999, 94 (10) : 227B - 227B
[29] A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome
Mattison, Ryan
Jumonville, Alcee
Flynn, Patrick James
Moreno-Aspitia, Alvaro
Erlichman, Charles
LaPlant, Betsy
Juckett, Mark B.
LEUKEMIA & LYMPHOMA, 2015, 56 (07) : 2061 - 2066
[30] A phase I study of SU11248 in the treatment of patients with acute myeloid leukemia (AML) refractory or resistant or not amenable to conventional therapy.
Fiedler, W
Serve, H
Döhner, H
Niederwieser, D
Ottman, OG
O'Farrell, M
Bello, C
Allred, R
Brega, NM
Massimini, G
Scigalla, P
Berdel, WE
Hossfeld, DK
BLOOD, 2003, 102 (11) : 616A - 616A

← 1 2 3 4 5 →